Epetraborole

Drug Profile

Epetraborole

Alternative Names: (S)-3-aminomethylbenzoxaborole; ABX; AN-3365; GSK '052; GSK-052; GSK-2251052

Latest Information Update: 26 Mar 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Anacor Pharmaceuticals
  • Developer Anacor Pharmaceuticals; GlaxoSmithKline
  • Class 2 ring heterocyclic compounds; Antibacterials; Benzene derivatives; Organic boron compounds; Small molecules
  • Mechanism of Action Leucyl-tRNA synthetase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Gram-negative infections
  • Discontinued Intra-abdominal infections; Urinary tract infections

Most Recent Events

  • 21 Mar 2013 AN 3365 is no longer licensed to GlaxoSmithKline. Anacor is considering its options for further development of the compound, if any
  • 21 Mar 2013 Suspended - Phase-II for Gram-negative infections in USA (IV)
  • 05 Oct 2012 Discontinued - Phase-I for Gram-negative infections in Australia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top